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Summarv A quantitatise polvmerase chain reaction (PCR) method for determining concentrations of mRN.A
for the cyclic AMP (cAMP)-binding protein RI alpha. a regulatory subum't of cAMP-dependent protein kinase.
A-as developed using site-directed mutagenic primers and mix-melt PCR. The PCR product for RI alpha
mRNA u-as modified to include an EcoRV' restriction site for use as an internal standard. This mutant utilised
the same primers as the target mRNA and differed in sequence by only four bases. As only one of these base
changes results in a purine pyrimidine sWitch the effective change in labelling with [3-P]dCTP A-as less than
0.50O. Reverse transcription of mRNA was performed and quantitatisve PCR was carried out using fixed levels
of mutant RI alpha *s varying amounts of both normal RI alpha sequence of know-n concentration and
unknown samples. Validation of the technique using rigourous quality control established that reverse
transcription. determined by incorporation of labelled nucleotides. gave intra- and interassay sariations of 16.2
and 9.3°o respectixely. Using crossover evaluation of cDNA concentrations with cloned RI alpha sequences as
controls intra- and interassay variations of 14.3°o and 4-8°o respectiselv were obtained. Using compounded
errors. the limits of precision for this technique demonstrate that values that are altered by 500o or more
represent a true alteration in mRNA levels betw-een samples tested. This value compares fasvourably to similar
s-alues for radioimmunoassays of betu-een 100o and 300o precision. Analysis of a series of patient samples
during routine follow-up of treatment demonstrated clear changes in mRNA lesels. Using site-directed
mutagenesis to establish a quantitative PCR-based assay for expression of mRNA this study demonstrates the
potential usefulness and some limitations of quantitative PCR for applications Within a clinical biochemistry
laboratory. How-ever. based on compounded error. values that vary by less than 50%O Within assays. and by less
than 700o in separate assays could not be clearly separated. Assessment of paired patient samples has
demonstrated clear changes in mRNA for the target protein RI alpha. With the use of normal quality control
procedures this study has established that the degree of reproducibility of this quantitative PCR technique
u-ould allou- assessment of mRNA lesvels for markers of interest in clinical samples in a routine laboratory
context.
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Accurate and precise quantitation of mRNA levels is
becoming an increasingly important methodology in research
applications. In addition. as our understanding of disease
processes improves so the potential for mRNA DNA-based
assays in clinical management increases. Overexpression or
amplification of oncogenes. expression of viral RNA and
many other aspects of molecular diagnostics require the
measurement of mRNA levels often in small samples or in
low- abundance. Many diverse methods for the qualitative
and quantitative analIvsis of mRNA exist. but arguably onIl
one. the polymerase chain reaction (PCR). is capable of the
degree of sensitiVity and ease of execution required for
routine application. Major advances in the development of
semiquantitative and quantitative PCR assavs have been
made over recent years. How-ever. as Xet. the issue of
reproducibilitv and accuracv of such assays has not been
addressed. For such a technique to provide valuable clinical
information it will hasve to take its place along with other
routine measurements. such as immunoassays. receptor
measurements and other functional clinical biochemistrx
tests. In such applications the limitations of the technique
w-ith regard to reproducibility. accuracy and detection limits
must be clearly defined.
Tumour cvtosolic levels of cyclic AMP (cAMP)-binding
proteins. the regulator- subunits of cAMP-dependent protein
kinase (RI and RII) have been shown to be associated with
disease behaViour in patients with early breast cancer. high
binding relating to poor prognosis (Battersby et al.. 1994:
Miller et al.. 1993a). Recent studies have shown that high
levels of total binding are concomitant with a relative
overexpression of the RI subtype (Miller et al.. 1993b).
which in breast cancer is respresented by the RI alpha
isoform. Novel therapeutic approaches based on the targeting
of such molecules have been developed and are showing
promise (Cho-Chung. 1992: Sheffield. 1991). To date protein-
binding studies have been used to establish the importance of
RI alpha cAMP-binding protein but such measurements are
neither sensitive nor selective enough to be applied to fine-
needle aspirates (FNAs) which are a routine means of
sampling breast tumours. Nevertheless. evidence exists to
suggest that measurement of RI alpha could provide useful
information in the selection of patients for therapy and in
establishing prognosis. It remains to be established whether
variations in expression of mRNA for RI alpha can provide
useful additional data for the evaluation of the role of the
cAMP messenger system in the natural histor- of breast
cancer.
In order to address this issue. a quantitatis e PCR
technique A-as established for the measurement of RI alpha
mRNA levels in breast cancer samples. The technique was
validated for intra-assav and interassay precision and
-ariation. In addition the sensitivitv and detection limits of
this technique were further tested. The aim of these studies
was to establish the applications and limitiations of PCR-
based mRNA measurements in this important clinical
problem. In so doing. the applicability of the quantitative
PCR approach described here for use in a routine patient
esaluation for any marker of interest has been demonstrated.
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Materials and methods
PCR of human cA4.1fP-dependent protein kinase type I-alpha
subunit
The sequence for the cDNA of human cAMP-dependent
protein kinase type-I-alpha subunit isolated from human
testis (Sandberg et al.. 1990) wxas retrieved from the Gembl
database (accession no: M33336). Using this 3036 bp
sequence PCR primers were designed that amplified the
region from bases 159 -589. The resultant 430 bp fragment
codes entirely for mRNA. which is subsequently' translated
into protein.
mR.V.4 extraction
Total cellular RNA %vas extracted from frozen tissue using
the lithium chloride-urea method (Bartlett et al.. 1992).
Before RNA extraction. c. 200 mg of tumour tissue was
homogenised using a tissue dismembranator (Braun. Ger-
many) at -20-C. Pelleted RNA was resuspended in distilled
water and the concentration and purity assessed by-
measuring absorbance at 260 and 280 nm.
Rev erse-transcriptase polv merase chain reaction RT-PCRV
RT-PCR was carried out using a Techne PHC-3 thermo-
cycler. For the reverse transcription assay. 1 jig aliquots of
total cellular RNA were denatured for 10 min at 65-C then
reverse transcribed by incubation with 100 ng of a random
hexamer oligonucleotide. with 2 mm each dATP. dTTP.
dCTP and dGTP (Pharmacia. UK). 200 units of Superscript
(Life Technologies. Paisley. UK) reverse transcriptase for 1 h
at 42-C in a total volume of 20 ,l. Reverse-transcribed
cDNA was stored at -20'C before analyssis by PCR. All
cDNA were amplified using a housekeeping gene GAPDH to
ensure RNA was intact before further analysis.
To establish the reproducibility of the reverse transcriptase
reaction. the following experiments w-ere performed.
(1) Five RNA samples u-ere reverse transcribed as described
above. in triplicate. but uith the addition of 0.5 ,Ci
[`S]dATP. This experiment w-as repeated on three
separate occasions.
(2) A single RNA sample >-as rexerse transcribed in a
similar manner. in ten separate reactions. This experi-
ment was repeated fixve times.
Following the rexverse transcription reaction. the resultant
cDNA was precipiated by the addition of 5 mg of tRNA
(Sigma) 20 ,ul 7.5 M ammonium acetate. 180 p1 water and
300 ,ul absolute ethanol to each sample. After mixing. the
sample uas cooled on drx' ice for 30 min. centrifuged at 4-C
for 15 min at 15 000 r.p.m. and the supematant discarded.
The pellet was washed with 300 pl 70% ethanol. cooled on
drx ice and centrifuged at 4^C for 15 min at 15 000 r.p.m.
and the supernatant discarded. The pellet was then dried.
resuspended in 200 pl of water solubilised in 3 ml of
scintillation cocktail and counted.
For unlabelled PCRs 1 p1 of cDNA was added to 0.5 pMI
of each primer in a v-olume of 50 pl1. Before PCR this reaction
w-as heated to 94^C for 10 min and then cooled rapidly to
4 C. PCR reactions u-ere performed in a final volume of
100 p1 containing the following: 0.5 units of Taq poly'merase
(Applied Biosystems. UK). 1.25 m-M dATP. dTTP. dCTP and
dGTP (Pharmacia. UK). 0.5 pM-i of each primer in 50 mm
potassium chloride. 10 mNi Tris-HC 1. 0.1°o Triton-X and
2.5 mM magnesium chloride. Reactions were overlaid w-ith
100 p1 of paraffin oil.
The amplification reaction was carried out oxver 30 cycles
with the following parameters: Step 1. 94-C for 38 s: step 2.
50 C for 53 s: step 3. 722C for 68 s. For the final cycle. the 72-C
step A-as extended to S min to ensure all transcripts 'ere full
length. The primers used in these reactions are shoxx-n below:
PCR primers:
RI alpha 430 sense:
5'-GCATAACATTCAAAGCACTGC-3'
RI alpha 430 antisense:
5'-CTTGCTGAATCACAGTCTCTCC-3'
Site-directed mutagenesis
In order to provide an internal standard for PCR
quantitation of mRNA levels. site directed mutagenesis w'as
used to insert an EcoRV restriction enzyme site halfway
along the PCR amplimer. The method used to introduce the
restriction enzyme site was based on the PCR. Essentiall.
two further oligonucleotides were svnthesised. flanking the
central portion of the cAMP RI alpha-binding protein PCR
amplimer. These oligonucleotides contained an EcoRV
restriction site to be introduced by mismatch PCR into the
amplimer. Using touch-do'n PCR two fragments represent-
ing the 3' and 5' portions of the PCR amplimer were
synthesised. These were shoxx'n to include the restriction site
by restriction digest of the PCR fragments. The full mutation
containing 430 bp RI alpha amplimer was then synthesised
follo'ing melting and reannealing of the 3' and 5' portions
followed by PCR of the annealed DNA using the normal
flanking primers for the RI alpha 430 bp fragment (Figure 1).
Primer 1 Primer 2
PCR 1
R
RI alpha 4.30 product (control)
Primer 1
Mutant 1
PCR 2
Mutant 2
3' RI alpha fragment
Primer 2
5' RI alpha fragment
mix-melt
Primer 1
Primer 2
RI alpha 430 EcoRV product (mutant)
Figure 1 Site-directed mutagenesis bx mix -melt PCR. Uisine the
430bp frazment of RI alpha alpha cDN-A as a template (RI a430
tw-o separate PCR reactions are performed as folloxx s: The 3
normal RI alpha primer is PCR with a 5' mutant primer includine
an EcoRN restriction site and flanking the central 30 bases of the
RI alpha amplimer. Simultaneously. a 3 mutant primer x-as co-
amplified with the 5' normal primer to gise a second PCR
product. These products each 230bp in length were then mixed
and denatured (mix-melt) and the resultant conjugants annealed
across the mutated restriction site selected by- PCR using the
normal 3' and 5' primers yielding a 430bp RI alpha cDN-A with
an internal restnrction enzyme site.cP RI alpha mRN i ba-s cancer
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Inclusion of the EcoRV site into the 430 RI alpha amplimer
was confirmed by restriction digestion ofthe 430 bp fragment
into two identical 215 bp fragments. To provide a readily
available stock of these fragments, both mutated and normal
PCR products were cloned into the pCRII vector
(Invitrogen).
Quantitative PCR reaction
Aliquots of each cDNA sample (5 Ml) were co-amplified with
100, 10, 1 and 0.1 pg of RI alpha mutated plasmid. Fixed
concentrations of normal RI alpha product (10 and 100 pg)
were also co-amplified with a range of concentrations (0.1-
100 pg) of cloned mutated RI alpha product. PCR
amplification was over 26 cycles (94°C 38 s, 55°C 53 s,
72°C 68 s) followed by extension at 72CC for 5 min. PCR
reactions were performed in a final volume of 100 p1
containing the following: 0.5 units of Taq polymerase,
1.25 mm dATP, dTTP and dGTP, 0.5 mM dCTP, O.lyCi
[3PJWdGTP (Amersham), 5 pM of each primer in 50 mM
potassium chloride, 10 mM Tris-HC1, 0.1% Triton-X and
2.5 mM magnesium chloride. Reactions were overlaid with
100 p1 of paraffin oil. The reaction mixtures were then
restriction digested with 5-10 units of EcoRV in PCR buffer
with 100 mm sodium chloride added to ensure optimal
digestion conditions for the enzyme at 37°C for 2 h.
Labelled PCR fragments were separated on a 6% acrylamide
gel at 30 mA for 2-3 h. Gels were fixed for 0.5-1 h in 5%
acetic acid, 40% methanol, 10% glycerol, before drying at
80°C for 1-2 h. Gels were exposed to preflashed X-OMAT
film for 1-8 h, using radioactive ink as a marker in order to
correctly orientate the gels with respect to the autoradio-
graphs. Bands corresponding to the normal and mutant
component of each reaction were excised and '3P incorpora-
tion assessed by Cerenkov counting. The relative counts per
band were plotted and the point of equal labelling between
the unknown sample and mutant DNA taken as the
concentration of unknown cDNA. As a control 100 pg and
10 pg of normal plasmid were included in each experiment in
place of sample cDNA (Figure 2) to monitor assay variation.
For each assay an additional negative control sample, no
cDNA, was included, to check for crossover contamination,
and 100 pg of mutant plasmid in the absence of normal RI
alpha was amplified to monitor the efficiency of the
restriction digestion.
Sensitivity
The sensitivity of the assay was established using cloned RI
alpha 430 cDNA. Concentrations of RI alpha cDNA were
calculated based on the concentration of the insert in pCRII.
The molar equivalent for RI alpha mRNA with respect to
plasmid added is 0.34 fmol RI alpha mRNA pg-' RI alpha
plasmid added (430 bp RI alpha fragment in 3900 bp pCRII
vector). In order to establish the sensitivity of this technique,
cross-over experiments for 1 pg, 0.1 pg and 0.01 pg of
plasmid were also carried out. For these experiments PCR
was performed over 30 cycles.
Intra- and interassay variation
Using RI alpha plasmid as a control, intra- and interassay
variations were calculated over eight sequential assays. For
intra-assay variations repeat control samples were determined
withinthesameassayandthemeanandstandarddeviation(s.d.)
determined, the value quoted is the average percentage intra-
assay variation (s.d./mean) from three assays. For inter-assay
variation thevalues obtainedforeachqualitycontrol (high and
low) were calculated and the mean and standard deviation of
thesevaluesoverallincludedassaysusedtocalculatepercentage
inter-assay variation (s.d./mean as percentage).
Results
Reproducibility of the reverse transcription reaction
In five separate experiments a pooled tumour RNA sample
was reverse transcribed in 10 or more aliquots and the
Quantitative pcr
Plasrndcontrols
100 pg RI alpha
normal plasmid
EaiLnt sample
10 pg RI alpha
normal plasmid
100 10 1 0.1 100 10 1 0.1 Blank 100 10 1 0.1 Cut
pg mutant pg mutant control pg mutant mutant
RI alpha plasmid RI alpha plasmid RI alpha plasmid
Fgee 2 Quantitative PCR with control plasmid and unkrnown samples. The results of a typical quantitative PCR reaction are
shown. From left to right on the gel figure lanes 1-4 labelled lOOpg RI alpha above and 100, 10, 1 and 0.1 below (from left to
right) contain PCR products, digested with EcoRV from a reaction mixture ofc. lOOpg normal RI alpha plasmid (upper band) and
decreasing (100-0.lpg) mutant plasmid (lower band). Lanes 5-8 labeled above lOpg RI alpha and 100, 10, 1 and 0.1 below
contain PCR products from a dilution of mutant plasmid against lOpg normal plasmid. Lane 9 labelled below Blank control is a
DNA free control. Lanes 10- 13 labeUled Patient sample above and 100, 10, 1 and 0.1 below show reaction products from a sample
of unknown concentration of cDNA for RI alpha diluted against mutant plasmid (lower band 100-0.1 pg) with a cross over
between upper and lower bands between 10 and 1 pg mutant plasmid. The right-hand lane labelled 14 Cut mutant shows complete
digestion of RI alpha EcoRV mutant PCR product in the absence of any normal RI alpha cDNA or plasmid.cAP RI -1 nd in broad cancer
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incorporation of[35SIdATP quantified. The variation observed
was assessed by representing the standard deviation as a
percentage ofthe mean value for counts incorporated. Over all
experiments, the mean variation was 16.2% (range 8-27%).
Between experiments the variation assessed using the average
value obtained for each assay was 9.3% (Table I).
In a separate series of experiments, five separate RNA
samples were reverse transcribed in triplicate. The mean
counts incorporated were determined and the coefficient of
variation calculated as for the results shown in Table I. Over
three experiments the coefficient ofvariation (intra-assay) was
14.6% (data not shown).
cDNA quantitation
The results ofa typical assay are shown (Figure 2). Following
co-amplification and restriction digestion of cloned cDNA
from both mutant and normal RI alpha inserts two bands are
clearly visible on the autoradiograph (Figure 2). The sizes of
these bands correspond to PCR products of 430 and 215 bp
respectively. In the absence ofany normal cDNA (lane 14) all
cDNA is cleaved to form a 215 bp product. In the absence of
mutant cDNA no cleavage of the 430 bp normal fragment is
observed (data not shown).
In the assay shown (Figure 2), mutant RI alpha cDNA is
co-amplified in decreasing concentrations with known (lanes
1-8) or unknown (lanes 10-13) concentrations ofnormal RI
alpha cDNA. At high concentrations of mutant RI alpha
cDNA the 215 bp band, representing the cleaved mutant
PCR amplimer, represents the major PCR product. As the
concentration of mutant RI alpha cDNA is decreased the
relative intensity of the 215 bp band decreases; also the
intensity of the 430 bp band, representing unmutated RI
alpha cDNA, increases until a point is reached where RI
alpha normal cDNA represents the majority of the PCR
template. At this point the intensity of the two bands is
reversed with the lower band becoming less intense than the
higher. This 'cross-over' point represents the point at which
the two templates are present at equal concentrations within
the PCR reaction tube and therefore are equally susceptible
to PCR amplification. The approximate concentration of RI
alpha cDNA can be estimated from the gel shown here
(Figure 2). More precise quantitation is achieved by excising
the radiolabelled bands, counting the incorporated [32P]dCTP
and plotting the incorporated counts for each band against
the concentration of added mutant RI alpha cDNA (Figure
3). This method allows an estimation of the theoretical cross-
over point for the PCR reaction, giving a more precise value
for the concentration of RI alpha cDNA in the unknown
sample.
Assay sensitivity and limit ofdetection
Standard assay conditions were established using a range of
cDNA concentrations from 34 fmol to 3.4 amol (10-14-
10l0 M, 100-0.1 pg) RI alpha mutant cDNA. Using these
conditions the limit of sensitivity was approximately 10 amol
(1.0 pg DNA). By decreasing the range of controls used to
establish the unknown concentration (to between 10 and
Table I Quantitation of cDNA production in reverse transcriptase
assay
Counts Intra-assay variation
Expt. no. (mean+s.d.) (%)
1 21257+2897 13.6
2 18312+4995 27.3
3 17723+3105 17.5
4 17314+ 1383 8.0
5 20602+3896 18.9
Mean intra-assay variation 17.0
Interassay variation 19042+1775 9.3
0.1 fg mutant mutant plasmid) and increasing the number of
PCR cycles to 30 the limit of detection was reduced from
1 amol under standard conditions to 0.002 amol (2 x 10-21 M,
approximately 1000 copies) of cDNA in these extended PCR
assays (data not shown), concentrations below this range
have not been tested.
Intra- and interassay variation
Following two such experiments the mean intra-assay
variation was 14.3%. Using this approach interassay
variations of 3.6% (high control sample) and 8.0% (low
control sample) were obtained over eight assays.
Compound error
As co-efficients of variation within each stage of the assay
procedure have been determined, it is possible to calculate
confidence limits for values obtained using this quantitative
PCR technique. These were calculated by compounding error
at each stage of measurement, reverse transcription, intra-
assay variation and interassay variation. In the case ofpaired
samples measured within the same assay, error due to
interassay variation was ignored. For such samples the RI
alpha intra-assay concentration range (C,) was defined
between the maximum (C, 3) and minimum (C, ,,) values
obtained from the observed (CO values) where:
Ci = Co(1 + E,)(1 + Vi) and Ci:rm = Co(1 -E)(- V,)
where E is the assay variation for reverse transcriptase
reaction, V is the assay variation for PCR and i is the intra-
100 F
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1
0.1
0.01 II
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Patients
Fugwe 3 Pre- and Post-treatment mRNA levels for 12 patients
with breast cancer. Following quantitative PCR as described
above pre- (-) and post- (1A) treatment values for RI alpha
mRNA (fmol RI alphaug- RNA) were determined for each
patient. Six patients showed markled falls in RI alpha mRNA
during treatment (A-F, note log scale). Four patients (G-J)
showed no detectable change (patient J pre- and post-values were
identical). A further two patients (K and L) showed marked
increases in mRNA levels for RI alpha during the observation
period. Error bars represent 95% confidence intervals for RI
alpha mRNA concentrations as assessed by this technique.uAW RI - nm ihbes cancer
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assay variation. Similarly, where necessary interassay
concentration ranges (Cb,) were defined between the
maximum (Cb .) and minimum (Cb m) values obtained
from the intra-assay values (Ci) where:
Cb = Ci(1 + Eb)(1 + Vb) and Cb mi. = C1(1 - Eb)(1- Vb)
with b denoting inter-assay (between) variations for each step.
For samples assayed within a single assay such errors would
account for a variation of +31% or -27% in the obtained
values whereas for samples compared between assays
variations of +71% or -53% could be expected. As all
samples described here were compared within assays, for
purposes of this assay we have regarded a change of greater
than 50% as being representative of a significant difference
between test samples.
Quantitation of RI alpha mRNA in breast cancer sanples
This system of measurement has been applied to a test
population of 12 breast cancer patients for whom tissue was
available pre- and post treatment (Figure 3). Pre- and post
treatment samples were assayed in the same PCR and reverse
transcription run to minimise changes due to these variables.
Under these conditions an assay sample with a concentration
of 1 fmol mRNA would produce results within the range
0.73-1.31 fmol (calculated from intra-assay variations).
Assuming the maximum error for paired samples, a decrease
of greater than 46% (i.e. to less than 54% of the
pretreatment value) or an increase of greater than 85% (i.e
to 185% ofthe pretreatment value) in RI alpha mRNA levels
detected was calculated to reflect a true change in RI alpha
levels. Using the values obtained for the 12 patients tested
pre- and post treatment, the confidence interval for each
sample was determined in fmol RI alpha mRNA. In addition
the confidence interval for the change in RI alpha mRNA
concentrations post treatment was assessed as a percentage of
the pre-treatment value (Figure 3). Using these criteria, six
patients (A-G) showed a decrease in RI alpha mRNA over
time, four (H-K) showed no significant change while two
(L-M) showed a marked increase in RI alpha mRNA.
In this report the objective evaluation of a method for
developing and utilising quantitative reverse-transcriptase
polymerase chain reactions (RT-PCR) was performed.
Many different methods have been used for the measurement
ofmRNA concentrations by PCR; however, to date relatively
few investigators have paid close attention to the reproduci-
bility of this important technique. The methods employed
here were selected to provide accurate quantitation and the
potential for use in a large-scale automated or semiautomated
PCR-based assay system. In order to achieve this goal, a two-
step assay, involving reverse transcription followed by PCR
was evaluated.
Using pooled RNA to investigate the variation introduced
by reverse transcription of mRNA present within (16.2%)
and between (14.6%) samples in a single assay lie within
acceptable limits (Table I). In addition, variation between
assays can be controlled to within 10% for individual
samples. This allows the use of a more simple cDNA PCR
quantitation rather than the use of control RNA from the
mutated cDNA product for inclusion within the reverse
transcription reaction. This approach, which is theoretically
more accurate, requires measurement of significantly more
samples per patient to provide accurate quantitation.
Intra- and interassay coefficients of variation have been
investigated in the PCR stage of the assay to establish the
potential limitations of accuracy for this technique. Using the
methods described above intra-assay variation was 14.3%
whereas interassay variation remained below between 4% and
8%, for low and high controls, over eight assays. Standard
radioimmunoassays (RIAs) will commonly have intra- and
interassay variations between 5% and 12%. In our view while
this technique is as yet less consistent than RlAs the variation
observed shows that differences in mRNA expression of
greater than 50% will be readily detected using this system. By
using the errors involved in both the reverse transcription
assays and the PCR reaction confidence intervals for values
obtained were calculated as the obtained value +31% or
-27%. This compares favourably with conventional steroid
assays involving extraction and immunoassay with confidence
intervals of around +20% (Bartlett et al., 1987, 1989). These
calculations do not control for systematic errors which could
be highly reproducible, however we have not identified any
such source of error in our system. In tumour tissue from a
limited series of patients we have shown changes in mRNA
levels ranging from decreases of up to 99% to increases of
over 4000%. This suggests that for the mRNA species for
which this assay was designed the accuracy and reproducibility
observed in this study provide an acceptable measurement of
mRNA changes in these samples.
In common with other studies (JessenEller et al., 1994;
Izutani et al., 1994) the quantitative PCR reaction described
here could detect and quantify around 1000 copies of mRNA
within each sample. This would allow detection of abundant
mRNAs from samples of as few as ten cells or less, whereas
samples ofperhaps 1000 cells would be required for low copy
number mRNA species. Using mRNA prepared from cells
cultured in 1.3 cm2 wells we have shown that this method can
be applied to samples with low cell numbers (data not
shown). While 200 mg oftumour material was used for initial
mRNA extraction this provided sufficient material for other
investigations; in addition, the RT-PCR technique used here
required less than 2% of the mRNA extracted from these
samples. Therefore, while this technique has yet to be tested
directly on FNA-derived samples it is clear that such
applications are feasible.
Increasingly in both oncology and other disciplines the use
of quantitative measures of gene expression and amplification
are being shown to have clinical significance. As with steroid
RLAs in the early 1970s methods are being sought that can
rapidly and reproducibly estimate mRNA levels in a clinical
laboratory context. Applications ranging from toxicology
(Raval, 1994), obstetrics (Bianchi et al., 1994), disease
prognosis and treatment (Seeger et al., 1985; Brodeur et al.,
1984) and drug resistance (Withoff et al., 1994; Lyttelton et
al., 1994) may require such methods in the near future. In
addition a wide range of research applications are currently
using RT-PCR or PCR to assess mRNA and DNA changes
in experimental situations. In the absence of accurate and
reliable quality control data the significance of the observed
changes remains open to question. Recently some investiga-
tors have sought to approach this problem by the use of
quality controls and the assessment of assay variation in
studies of gene amplification and mRNA expression (Withoff
et al., 1994; Lyttelton et al., 1994). The study presented here
provides an evaluation of the errors associated with each
stage of an RT-PCR method for the measurement of a
potential marker of clinical significance in breast cancer. In
evaluating these parameters this study has identified and
quantified the potential for variation at each stage of the
measurement of mRNA from human tissue.
Use ofPCR for quantification presumes that the criteria for
such analyses are met. In any PCR with more than one target
molecule the ratio of the PCR products on completion of the
reaction willreflect the ratio present in the pre-PCR sample
providing the efficiencies of primers and labelling for both
products are equal (Withoff et al., 1994). Any variation in the
efficiencies of primer hybridisation or product synthesis will
reduce the power of the PCR product to accurately reflect the
concentration of targets within the pre-PCR sample.
Effectively there are three methods by which quantitative
or semiquantitative analysis of DNA concentration may be
achieved using PCR. These involve: (1) use of an alternativecAW RI -*1. m in hsest canoer
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PCR as a control, or use of a single PCR with artificially
altered products as control to allow quantitation by (2) use of
a size-altered product with a single PCR or (3) use of an
artificially introduced restriction enzyme site to allow
separation of unknown sample from control.
The first of these methods is theoretically the least
quantitative as it relies on the amplification of separate
products with primers of differing sequence, annealing
characteristics and requirement for reaction components
(specifically dNTPs). Use of such reactions will conflict with
the requirement for equal primer efficiencies required for
accurate quantitation. Such 'competitive' PCR reactions are
however relatively simple to establish and provide a useful
tool for researchers who require a relatively simple
comparison of concentrations between samples. These
methods, although limited, have been shown to provide
accurate semiquantitative assessments of DNA or cDNA
levels (Underwood et al., 1994; Chan et al., 1994; Lubin et
al., 1991; Siebert and Larrick, 1992; Frye et al., 1989).
In order to avoid these problems, many researchers have
made use of mutated PCR products to provide controls
within PCR vessels. The aim of these methods has been to
circumvent the problems associated with primer sets with
differing annealing efficiencies and to provide a more accurate
standard for the quantitation of DNA levels. The use ofPCR
products which have been altered by the insertion of 100-
200 bp of random DNA between the primer binding sites
provided a significant improvement in terms of reproduci-
bility and quantitation of DNA species. By eliminating the
requirement for a competitive PCR template to be included,
the problems associated with separate primer sites were
removed. This approach would appear to circumvent the
problems of unequal amplification efficiencies caused by
differing primer sets. However, it is known that products of
differing size within a single PCR will show preferential
amplification ofthe smaller product (Underwood et al., 1994;
Chan et al., 1994; Frye et al., 1989). Such amplification errors
can result in ratios of products varying by up to 300% over
25-35 cycles (Withoff et al., 1994; Frye et al., 1989) when
different regions of a single gene are amplified. A theoretical
variation of amplification efficiency of as little as 3% can
result in a 2 to 3-fold difference in end product ratios. Use of
internal labelling of PCR products can further compound
such errors as larger PCR products will by nature include
more labelling sites than shorter ones (Frye et al., 1989).
As these problems were appreciated and as the potential
for PCR-based assays for use in clinical management of
disease become more apparent the need for an accurate,
quantitative and potentially automatable system was clear.
Such a system has been developed with the use of site-
directed mutagenesis of PCR products to provide a PCR
control template that has minimal modifications in sequence
to introduce a novel restriction enzyme site within the PCR
product. With primer sites and size identical to the target
sequence this product (control) can then be differentiated
from the unknown following a simple enzymatic digestion.
The advantages of this system are that by maintaining
maximum identity between the control (mutated form) and
sample (normal form) DNA the reaction kinetics for both
products are essentially identical, and so minimise errors due
to the PCR reaction itself. In this study a variation in
sequence reflecting one base change (0.2%) was achieved.
Such an approach maxises the potential for accuracy of
PCR quantitation. Furthermore, while it is possible to use
conventional size separation to distinguish the control and
sample PCR products, as in this preliminary study, the use of
biotinylated and fluorescence-based primers would allow this
system to be automated for use on a plate-reader system or
on an automated DNA sequencer. This flexibility provides
the potential for the development of automated PCR-based
assay systems that have the potential for application within
the clinical environment using established technologies. In the
light of these possibilities, and since the experimental systems
under investigation required the ability to accurately quantify
mRNA from tumour specimens this approach was used to
evaluate the use ofquantitative PCR as a potential diagnostic
tool.
In breast cancer patients high levels of tumour cDNA-
binding proteins have been shown to be associated with poor
prognosis in terms of both disease recurrence and overall
survival (Battersby et al., 1994; Miller et al., 1993a). This
association is independent of known established prognostic
factors and allows the identification of a small subgroup of
patients whose outlook warrants the implementation of
aggressive systemic therapy. Further investigations suggest
that differential expression ofcertain forms ofcAMP-binding
protein are of significance in producing this relationship
(Battersby et al., 1994; Miller et al., 1993a; Miller et al.,
1993b). Moreover, whereas measurement of binding protein
levels requires large amounts of tissue, it should be possible
to determine mRNA levels for specific cAMP-BP isoforms in
small (FNA) samples of breast tissue. The relationship
between these parameters is currently under investigation.
This could provide a rapid and robust method for evaluating
the relationships between RI alpha expression, disease
response to treatment and the usefulness of aggressive
therapies. Using the quantitative PCR system described
above, mRNA levels have been assessed in breast cancer
patients and differences in RI alpha expression identified, the
clinical significance of which will be further evaluated.
In conclusion, this study has demonstrated that, with the
inclusion of adequate quality control assessment and by
appropriate design, PCR can be used as a practical
laboratory procedure when accuracy and reproducibility as
well as high level throughput are required. The methods
described here can be applied to the measurement of any
DNA or mRNA species for which a clinical demand becomes
apparent. Ongoing studies using this method are designed to
probe breast cancer patients to establish the clinical
importance of the specific mRNA species used in these
studies.
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